Search

Kara Renita Mcmillian

Examiner (ID: 13893, Phone: (571)270-5236 , Office: P/1627 )

Most Active Art Unit
1627
Art Unit(s)
1617, 1623, 1627, 1622
Total Applications
1197
Issued Applications
307
Pending Applications
111
Abandoned Applications
791

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16341526 [patent_doc_number] => 20200306176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => OSMOTIC PUMP CONTROLLED RELEASE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/366404 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366404 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/366404
OSMOTIC PUMP CONTROLLED RELEASE FORMULATIONS Mar 26, 2019 Abandoned
Array ( [id] => 14893737 [patent_doc_number] => 20190290634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE [patent_app_type] => utility [patent_app_number] => 16/364431 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22374 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364431 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/364431
COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE Mar 25, 2019 Abandoned
Array ( [id] => 14893739 [patent_doc_number] => 20190290635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => METHODS OF TREATING BRAIN CANCER USING AGENTS THAT ALTER ACTIVITY OF A METABOLIC PATHWAY [patent_app_type] => utility [patent_app_number] => 16/364436 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19278 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364436 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/364436
METHODS OF TREATING BRAIN CANCER USING AGENTS THAT ALTER ACTIVITY OF A METABOLIC PATHWAY Mar 25, 2019 Abandoned
Array ( [id] => 14893783 [patent_doc_number] => 20190290657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF A CANNABINOID RECEPTOR AGONIST AND RADIATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/365148 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16365148 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/365148
Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy Mar 25, 2019 Issued
Array ( [id] => 15524591 [patent_doc_number] => 20200054601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => NOVEL METHODS [patent_app_type] => utility [patent_app_number] => 16/362525 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362525 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/362525
NOVEL METHODS Mar 21, 2019 Abandoned
Array ( [id] => 14833229 [patent_doc_number] => 20190275015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/358311 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17723 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358311 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/358311
COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR Mar 18, 2019 Abandoned
Array ( [id] => 16549680 [patent_doc_number] => 10882829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Pharmaceutical compounds [patent_app_type] => utility [patent_app_number] => 16/351620 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15731 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16351620 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/351620
Pharmaceutical compounds Mar 12, 2019 Issued
Array ( [id] => 14497631 [patent_doc_number] => 20190192470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms [patent_app_type] => utility [patent_app_number] => 16/297590 [patent_app_country] => US [patent_app_date] => 2019-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16297590 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/297590
Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms Mar 8, 2019 Abandoned
Array ( [id] => 15041365 [patent_doc_number] => 20190331687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 16/290827 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16290827 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/290827
CANCER TREATMENT Feb 28, 2019 Abandoned
Array ( [id] => 14435393 [patent_doc_number] => 20190175568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS [patent_app_type] => utility [patent_app_number] => 16/277871 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277871 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/277871
Compositions for treating amyotrophic lateral sclerosis Feb 14, 2019 Issued
Array ( [id] => 17569876 [patent_doc_number] => 11318130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod [patent_app_type] => utility [patent_app_number] => 16/268230 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 111 [patent_figures_cnt] => 126 [patent_no_of_words] => 68483 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16268230 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/268230
2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod Feb 4, 2019 Issued
Array ( [id] => 14306481 [patent_doc_number] => 20190142944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => INJECTABLE IBUPROFEN FORMULATION [patent_app_type] => utility [patent_app_number] => 16/249884 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8948 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249884 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/249884
INJECTABLE IBUPROFEN FORMULATION Jan 15, 2019 Abandoned
Array ( [id] => 14563815 [patent_doc_number] => 20190209514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Treatment of Bladder Cancer by Local Administration of Taxane Particles [patent_app_type] => utility [patent_app_number] => 16/239527 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239527 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/239527
Treatment of Bladder Cancer by Local Administration of Taxane Particles Jan 3, 2019 Abandoned
Array ( [id] => 14563817 [patent_doc_number] => 20190209515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Treatment of Bladder Cancer by Intratumoral Injection of Taxane Particles [patent_app_type] => utility [patent_app_number] => 16/239529 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239529 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/239529
Treatment of Bladder Cancer by Intratumoral Injection of Taxane Particles Jan 3, 2019 Abandoned
Array ( [id] => 18642357 [patent_doc_number] => 11766410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Composition for preventing or treating dry eye syndrome containing a-humulene as active ingredient [patent_app_type] => utility [patent_app_number] => 16/963843 [patent_app_country] => US [patent_app_date] => 2018-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 2441 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963843 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/963843
Composition for preventing or treating dry eye syndrome containing a-humulene as active ingredient Dec 27, 2018 Issued
Array ( [id] => 16925245 [patent_doc_number] => 11046706 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => CCR2 receptor antagonists and uses thereof [patent_app_type] => utility [patent_app_number] => 16/233315 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30826 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233315 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/233315
CCR2 receptor antagonists and uses thereof Dec 26, 2018 Issued
Array ( [id] => 14621603 [patent_doc_number] => 20190224169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => Methods of Treatment of Hypertriglyceridemia [patent_app_type] => utility [patent_app_number] => 16/227440 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227440 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/227440
Methods of Treatment of Hypertriglyceridemia Dec 19, 2018 Abandoned
Array ( [id] => 14712523 [patent_doc_number] => 20190247325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCING OXIDATIVE STRESS [patent_app_type] => utility [patent_app_number] => 16/221244 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221244 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/221244
METHODS AND COMPOSITIONS FOR REDUCING OXIDATIVE STRESS Dec 13, 2018 Abandoned
Array ( [id] => 14578281 [patent_doc_number] => 20190216749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES [patent_app_type] => utility [patent_app_number] => 16/213927 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213927 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/213927
TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES Dec 6, 2018 Abandoned
Array ( [id] => 16468589 [patent_doc_number] => 20200370126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => COMPOSITIONS AND METHODS FOR CHARACTERIZING CANCER [patent_app_type] => utility [patent_app_number] => 16/767886 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767886 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/767886
COMPOSITIONS AND METHODS FOR CHARACTERIZING CANCER Nov 27, 2018 Abandoned
Menu